SCHEMBL1713716

SCHEMBL1713716

CC1=NC(=Cc2c[nH]c3ncccc23)C(=O)N1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 3/20 0.55
KMT2A Q03164 1/20 0.54
HASPIN Q8TF76 4/20 0.47
CCNT1 O60563 2/20 0.47
CDK9 P50750 2/20 0.47
CHEK2 O96017 1/20 0.44
CDK1 P06493 1/20 0.44
SRC P12931 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CDC7 O00311 6/20 0.42
MAP2K1 Q02750 1/20 0.40
AXL P30530 1/20 0.40
GPR84 Q9NQS5 1/20 0.39
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
LRRK2 Q5S007 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713712 1.00 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713971 0.87 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713968 0.87 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714530 0.84 CHEK1 (0.52) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL5100901 0.84 CHEK1 (0.52) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL13676714 0.84 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL5100892 0.84 CHEK1 (0.52) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714528 0.84 CHEK1 (0.52) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL4723748 0.83 RAB9A (0.50) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL4723744 0.83 RAB9A (0.50) CHEK1KMT2AHASPINCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 US disclosed
EP-2094699-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 Sanofi-Aventis (FR) 2009-09-02 EP disclosed
WO-2008046982-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 CHEK1 17/4885KMT2A 3256/4885HASPIN 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.